Helen of Troy results
This article was originally published in The Rose Sheet
Executive Summary
Personal care sales dropped 8.3% to approximately $161 mil. during the third quarter, firm reports Jan. 9. Net sales in Q3 were down 4% to $197.5 mil. Net earnings decreased 27.2% to $22.7 mil. Results were impacted by increased administrative and advertising expenses, among other factors, Helen of Troy says. Nine month sales were roughly flat at $455.2 mil., while net earnings to date were $42.7 mil., down 33.8%. Firm anticipates Q4 and FY 2006 (ending Feb. 28) revenues will be in the range of $120 mil.-$130 mil. and $575 mil.-$585 mil., respectively...
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.